

**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

1.-10. (Canceled)

11. (Previously Presented) A method for stimulating an immune response in a patient, comprising administering to the patient a composition comprising a first component selected from the group consisting of physiologically acceptable carriers and immunostimulants, and a second component selected from the group consisting of:

- a) a polypeptide sequence comprising SEQ ID NO:475; and
- b) polypeptides having at least 90% identity to the full length of the polypeptide set forth in SEQ ID NO:475, wherein said polypeptides having at least 90% identity are immunologically reactive with an antibody and/or T cell that reacts with the polypeptide set forth in SEQ ID NO:475.

12. (Canceled)

13. (Currently Amended) The method of claim 11 or 12 wherein said immunostimulant is selected from the group consisting of monophosphoryl lipid A, 3-de-O-acylated monophosphoryl lipid A, and a saponin, alone or in combination.